Bioventus LLC announced its stabilized hyaluronic acid product, indicated for mild to moderate knee osteoarthritis, will enter the Taiwan patient care market, according to a company press release.
The hyaluronic acid product, called Durolane, is a non-animal stabilized hyaluronic acid single-injection knee osteoarthritis (OA) treatment.
“The combination of a leading OA solution like Durolane and Taiwan’s robust economy gives Bioventus a terrific opportunity to establish itself and grow in this market,” Tony Bihl, chief executive officer of Bioventus, said in a press release. “Orthobiologic solutions from Bioventus are now available in six countries in the Asia Pacific region and we plan to build on this as we continue our international expansion.”
Sales and marketing will be handled through Eulogiums.
“We believe that only knee OA products with superior quality can withstand in the competitive market in Taiwan and we have confidence that Durolane is the one,” Kenny Liu, chief executive officer of Eulogiums Co. Ltd., said in the release.